Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG)

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 88; no. 1; pp. 57 - 62
• Main Authors: Kotsakis, A, Kentepozidis, N, Emmanouilidis, Ch, Polyzos, A, Agelidou, A, Vaslamatzis, M, Chandrinos, V, Agelaki, S, Vamvakas, L, Kalbakis, K, Katsaounis, P, Stoltidis, D, Nintos, G, Hatzidaki, D, Vetsika, E.K, Mavroudis, D, Georgoulias, V
• Format: Journal Article
• Language: English
• Published: Ireland 01-04-2015
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab - administration & dosage; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - secondary; Cisplatin - administration & dosage; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Disease-Free Survival; Drug Administration Schedule; Female; Hematology, Oncology and Palliative Medicine; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Male; Middle Aged; Pulmonary/Respiratory; Taxoids - administration & dosage; Treatment Outcome; Vinblastine - administration & dosage; Vinblastine - analogs & derivatives; Overall response rate; Sequential treatment; NSCLC; Vinorelbine; Cisplatin; Bevacizumab
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2015.01.012

Highlights • Platinum-based chemotherapy is considered the cornerstone of treatment for NSCLC. • Bevacizumab with sequential chemotherapy is feasible with manageable toxicity. • This regimen in some cases is very active and leads to durable responses.